Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?

被引:64
作者
Selmeci, Laszlo [1 ]
机构
[1] Semmelweis Univ, Fac Med, Dept Cardiovasc Surg, Budapest, Hungary
关键词
Antioxidant defence; apolipoprotein(a); oxidized albumin; oxidized fibrinogen; reactive oxygen species (ROS); CHRONIC-RENAL-FAILURE; GLYCATION END-PRODUCTS; CORONARY-HEART-DISEASE; HUMAN SERUM-ALBUMIN; C-REACTIVE PROTEIN; HUMAN BLOOD-PLASMA; HEMODIALYSIS-PATIENTS; BINDING-SITES; HUMAN APOLIPOPROTEIN(A); FIBRINOGEN FRAGMENTS;
D O I
10.3109/10715762.2011.602074
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In 1996, a novel oxidative stress biomarker, referred to as advanced oxidation protein products (AOPP), was detected in the plasma of chronic uremic patients. It was suggested that AOPP measure highly oxidized proteins, especially albumin. Recent data in turn appear to indicate that oxidized fibrinogen is the key molecule responsible for the AOPP reaction in the human plasma. Since fibrinogen is an acute-phase reactant, it is evident that during each episode of inflammatory response, the antioxidant capacity of the plasma is enhanced. In this context, fibrinogen can be regarded as a component of the antioxidant system of the plasma proteome. It was also demonstrated that oxidized fibrinogen is bound to apolipoprotein(a) of lipoprotein(a) via lysine binding sites. Thus, apo(a) could compete with plasminogen (and/or tissue plasminogen activator) for its binding sites of fibrin(ogen), causing inhibition of fibrinolysis, and thereby promote atherosclerosis and cardiovascular disease.
引用
收藏
页码:1115 / 1123
页数:9
相关论文
共 108 条
[51]   Fibrinogen is an antioxidant that protects β-lipoproteins at physiological concentrations in a cell free system [J].
Kaplan, IV ;
Attaelmannan, M ;
Levinson, SS .
ATHEROSCLEROSIS, 2001, 158 (02) :455-463
[52]  
Kirmizis D, 2006, MED SCI MONITOR, V12, pCR55
[53]   Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) β- and γ-chains [J].
Klose, R ;
Fresser, F ;
Köchl, S ;
Parson, W ;
Kapetanopoulos, A ;
Fruchart-Najib, J ;
Baier, G ;
Utermann, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (49) :38206-38212
[54]   Comparability of serum and plasma concentrations of haemostasis activation markers [J].
Korte, W ;
Riesen, WF .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (07) :627-630
[55]   Fibrinogen fragments and platelet dysfunction in uremia [J].
Kozek-Langenecker, SA ;
Masaki, T ;
Mohammad, H ;
Green, W ;
Mohammad, SF ;
Cheung, AK .
KIDNEY INTERNATIONAL, 1999, 56 (01) :299-305
[56]   IDENTIFICATION OF PROTEINS ASSOCIATED WITH APOLIPOPROTEIN A-I-CONTAINING LIPOPROTEINS PURIFIED BY SELECTED-AFFINITY IMMUNOSORPTION [J].
KUNITAKE, ST ;
CARILLI, CT ;
LAU, K ;
PROTTER, AA ;
NAYAVIGNE, J ;
KANE, JP .
BIOCHEMISTRY, 1994, 33 (08) :1988-1993
[57]   THE SIGNIFICANCE OF FIBRINOGEN DERIVATIVES IN PLASMA IN HUMAN RENAL-FAILURE [J].
LANE, DA ;
IRELAND, H ;
KNIGHT, I ;
WOLFF, S ;
KYLE, P ;
CURTIS, JR .
BRITISH JOURNAL OF HAEMATOLOGY, 1984, 56 (02) :251-260
[58]   Convergent evolution of apolipoprotein(a) in primates and hedgehog [J].
Lawn, RM ;
Schwartz, K ;
Patthy, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) :11992-11997
[59]   Impairments of the biological properties of serum albumin in patients on haemodialysis [J].
Lim, Paik-Seong ;
Cheng, Yueh-Mei ;
Yang, Shih-Ming .
NEPHROLOGY, 2007, 12 (01) :18-24
[60]   Markers of oxidative stress in uremia [J].
Lipinski, B .
KIDNEY INTERNATIONAL, 2004, 65 (01) :339-340